Literature DB >> 18796369

Molecular biology of pancreatic cancer.

Cristóbal Belda-Iniesta1, Immaculada Ibáñez de Cáceres, Jorge Barriuso, Javier de Castro Carpeño, Manuel González Barón, Jaime Feliú.   

Abstract

Pancreatic cancer is a leading cause of cancer death. This devastating disease has the horrible honour of close to equal incidence and mortality rates. Late diagnosis and a constitutive resistance to every chemotherapy approach are responsible for this scenario. However, molecular biology tools in cooperation with translational efforts have dissected several secrets that underlie pancreatic cancer. Progressive acquisition of malignant, invasive phenotypes from pre-malignant lesions, recent revelations on core signalling pathways and new targeted designed trials offer a better future for pancreatic cancer patients. This review will summarise recent advances in the molecular biology of pancreatic cancer.

Entities:  

Mesh：

Year:  2008        PMID： 18796369     DOI： 10.1007/s12094-008-0247-6

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


  60 in total

Review 1.  Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us.

Authors:  Lynn Hlatky; Philip Hahnfeldt; Judah Folkman
Journal:  J Natl Cancer Inst       Date:  2002-06-19       Impact factor: 13.506

2.  Suppression of tumorigenesis and induction of p15(ink4b) by Smad4/DPC4 in human pancreatic cancer cells.

Authors:  Bailu Peng; Jason B Fleming; Tara Breslin; Ana M Grau; Shuichi Fojioka; James L Abbruzzese; Douglas B Evans; Dan Ayers; Kyle Wathen; Tianai Wu; Kimberly D Robertson; Paul J Chiao
Journal:  Clin Cancer Res       Date:  2002-11       Impact factor: 12.531

3.  Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.

Authors:  Andrew J Aguirre; Nabeel Bardeesy; Manisha Sinha; Lyle Lopez; David A Tuveson; James Horner; Mark S Redston; Ronald A DePinho
Journal:  Genes Dev       Date:  2003-12-17       Impact factor: 11.361

4.  p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions.

Authors:  M S Redston; C Caldas; A B Seymour; R H Hruban; L da Costa; C J Yeo; S E Kern
Journal:  Cancer Res       Date:  1994-06-01       Impact factor: 12.701

5.  Exon III splicing of fibroblast growth factor receptor 1 is modulated by growth factors and cyclin D1.

Authors:  Guowei Chen; Jian Wang; Zhanbing Liu; Marko Kornmann
Journal:  Pancreas       Date:  2008-08       Impact factor: 3.327

6.  Murine pancreatic tumor cell line TD2 bears the characteristic pattern of genetic changes with two independently amplified gene loci.

Authors:  Bettina Schreiner; Florian R Greten; Dorotthe M Baur; Alexander A Fingerle; Ulrich Zechner; Christian Böhm; Michael Schmid; Horst Hameister; Roland M Schmid
Journal:  Oncogene       Date:  2003-10-02       Impact factor: 9.867

7.  Enhanced expression of 14-3-3sigma in pancreatic cancer and its role in cell cycle regulation and apoptosis.

Authors:  Ahmed Guweidhi; Jörg Kleeff; Nathalia Giese; Jamael El Fitori; Knut Ketterer; Thomas Giese; Markus W Büchler; Murray Korc; Helmut Friess
Journal:  Carcinogenesis       Date:  2004-04-08       Impact factor: 4.944

8.  INK4/ARF germline alterations in pancreatic cancer patients.

Authors:  P Ghiorzo; L Pastorino; L Bonelli; R Cusano; A Nicora; S Zupo; P Queirolo; M Sertoli; V Pugliese; G Bianchi-Scarrà
Journal:  Ann Oncol       Date:  2004-01       Impact factor: 32.976

9.  An antibody directed against PDGF receptor beta enhances the antitumor and the anti-angiogenic activities of an anti-VEGF receptor 2 antibody.

Authors:  Juqun Shen; Marie D Vil; Haifan Zhang; James R Tonra; Ling L Rong; Chris Damoci; Marie Prewett; Dhanvanthri S Deevi; Jessica Kearney; David Surguladze; Xenia Jimenez; Michelle Iacolina; Rajiv Bassi; Kai Zhou; Paul Balderes; Venkat R M Mangalampalli; Nick Loizos; Dale L Ludwig; Zhenping Zhu
Journal:  Biochem Biophys Res Commun       Date:  2007-04-19       Impact factor: 3.575

10.  MUC1 expression is regulated by DNA methylation and histone H3 lysine 9 modification in cancer cells.

Authors:  Norishige Yamada; Yukari Nishida; Hideaki Tsutsumida; Tomofumi Hamada; Masamichi Goto; Michiyo Higashi; Mitsuharu Nomoto; Suguru Yonezawa
Journal:  Cancer Res       Date:  2008-04-15       Impact factor: 12.701
View more
  4 in total

1.  Mutant KRAS is a druggable target for pancreatic cancer.

Authors:  Elina Zorde Khvalevsky; Racheli Gabai; Itzhak Haim Rachmut; Elad Horwitz; Zivia Brunschwig; Ariel Orbach; Adva Shemi; Talia Golan; Abraham J Domb; Eylon Yavin; Hilla Giladi; Ludmila Rivkin; Alina Simerzin; Rami Eliakim; Abed Khalaileh; Ayala Hubert; Maor Lahav; Yael Kopelman; Eran Goldin; Alan Dancour; Yael Hants; Sagit Arbel-Alon; Rinat Abramovitch; Amotz Shemi; Eithan Galun
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-02       Impact factor: 11.205

2.  RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients.

Authors:  Talia Golan; Elina Zorde Khvalevsky; Ayala Hubert; Rachel Malka Gabai; Naama Hen; Amiel Segal; Abraham Domb; Gil Harari; Eliel Ben David; Stephen Raskin; Yuri Goldes; Eran Goldin; Rami Eliakim; Maor Lahav; Yael Kopleman; Alain Dancour; Amotz Shemi; Eithan Galun
Journal:  Oncotarget       Date:  2015-09-15

3.  Overexpression of GOLPH3 is associated with poor prognosis and clinical progression in pancreatic ductal adenocarcinoma.

Authors:  Luan-Jing Zhang; Ke-Bing Wang; Long-Shan Liu; Lian-Zhou Chen; Bao-Gang Peng; Li-Jian Liang; Zhi Li; Ling Xue; Wen Li; Jing-Tang Xia
Journal:  BMC Cancer       Date:  2014-08-07       Impact factor: 4.430

Review 4.  Exosomes and pancreatic diseases: status, challenges, and hopes.

Authors:  Xiao-Yu Guo; Fan Xiao; Jie Li; Yi-Nan Zhou; Wang-Jun Zhang; Bei Sun; Gang Wang
Journal:  Int J Biol Sci       Date:  2019-07-20       Impact factor: 6.580
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.